Zeteletinib Explained

Drug Name:	Zeteletinib
C:	25
H:	23
F:	3
N:	4
O:	4
Iupac Name:	2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide
Cas Number:	2216753-97-6
Chemspiderid:	115007145
Pubchem:	134391533
Unii:	EP0P7SHM0U
Chembl:	5095497
Smiles:	CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F
Stdinchi:	1S/C25H23F3N4O4/c1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16/h5-6,8-13H,7H2,1-4H3,(H,31,33)
Stdinchikey:	KOLQINCWMXQEOF-UHFFFAOYSA-N

Zeteletinib (BOS-172738, DS-5010) is an experimental anticancer medication which acts as a RET inhibitor.^[1] ^[2]

Notes and References

Vodopivec DM, Hu MI . RET kinase inhibitors for RET-altered thyroid cancers . Therapeutic Advances in Medical Oncology . 14 . 17588359221101691 . 2022 . 35756966 . 9218446 . 10.1177/17588359221101691 .
Gou Q, Gan X, Li L, Gou Q, Zhang T . Precious Gene: The Application of RET-Altered Inhibitors . Molecules (Basel, Switzerland) . 27 . 24 . December 2022 . 8839 . 36557971 . 9784389 . 10.3390/molecules27248839 . free .